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Abstract. In the last decade, success after in vitro fertilization process (IVF) has remained at a similar rate despite all 
the improvements implemented in the stimulation protocols and laboratory techniques. Hysteroscopy is a method 
becoming more widely used with patients after a failed IVF cycle, considering a large incidence of uterus cavum 
pathological states which have a negative impact on the favorable outcome. Numerous studies have provided different 
results on the IVF outcome with hysteroscopy performed prior to this treatment in cases with no uterus cavum pathology. 
The aim of the research was to examine the effect of both diagnostic and surgical hysteroscopy on the outcome of IVF.  
Hysteroscopy was performed with 74 patients 30 to 50 days prior to IVF and in 33 of them (group I) some pathological 
state was noticed, which was treated during the same procedure. The control group (group III) included 151 patients 
who had IVF performed with no prior hysteroscopy. There is no statistically significant difference in the rate of post 
hysteroscopy implantation between I and II group when compared to the control group (20.62% vs 23.28% vs 17.31%), 
nor in the rate of clinical pregnancies (45.45% vs 46.34% vs 34.44%). Following the correctional treatment of uterus 
cavum pathological states, implantation and pregnancy rates remain at a level comparable to hysteroscopically normal 
medical findings. Statistically significant higher pregnancy rate is present in group I after the first IVF cycle, compared 
to the next IVF in the same group and in comparison to the next IVF cycle in the control group (60.00% vs 27.91%, 
p<0.05). Hysteroscopy is a simple and safe method allowing nearly identical rate of clinical pregnancies after a surgical 
treatment of uterus cavum pathological states when compared to the control group, but statistically much higher 
pregnancy rate if the order of IVF procedure is being compared. In cases of normal ultrasound findings and negative 
hysteroscopical findings, performing hysteroscopy prior to IVF does not provide significantly better results. Therefore, its 
routine execution is not recommended. 
Key words: hysteroscopy, pathological states of the cavum, IVF outcome. 
Introduction 

 
In the last decade, pregnancy rate after IVF has remained 
almost the same, regardless of a lot of improvements im-
plemented in the stimulation protocols and the progress of 
the laboratory techniques. That being a major reason, more 
attention has been paid to the removal of all the pathologi-
cal states which could possibly have a negative impact on 
the endometrium receptivity, thus lowering the pregnancy 
rate after IVF [1,2]. Hysteroscopy is a superior method in 
uterus cavum visualization enabling a surgical treatment of 
the pathological changes within the same act. A remarka-
ble progress has been made with the inclusion of cameras, 
an optical system and a small sized hysteroscope itself, 
avoiding thus a cervical dilatation, alleviating pain during 
the intervention and enabling it to be performed in outpa-
tient conditions, without using anesthesia – office hyster-
oscopy [3]. It is widely accepted that hysteroscopy is per-
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formed after failed IVF cycles. However, there is still no 
agreed consensus on a required hysteroscopy prior to IVF 
cycle, especially in cases of normal cavum ultrasound 
findings. Numerous studies provide different data on IVF 
success when hysteroscopy is performed immediately prior 
to the IVF procedure [47]. 
For all these reasons, the aim of this research was to 
examine the influence of hysteroscopy on the IVF out-
come, both in cases with existing pathological substra-
tum in the uterus cavum and in cases with normal hys-
teroscopic findings. 
Methods 
The research was done at the Clinic of Gynecology and 
Obstetrics of the Clinical Center in Niš, as a prospective 
study, and it included 225 patients from the National 
IVF program.  
Criteria for inclusion in the research were: less than 
40 years of age, FSH < 15 IU/ml, AMH > 0.5, body 
mass index (BMI) < 30 kg/m², lack of genital infection 
and favorable karyotype of both partners. 
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Criteria for exclusion were: presence of chronic 
systematic disease, existence of hepatitis C or HIV in-
fection, organic pathology of the ovaries, the cause of 
immune infertility and azoospermia. 
The patients were divided in three groups: group of 
33 patients who had hysteroscopy performed prior to 
IVF, with existing uterus cavum pathology treated 
within the same procedure; II group of 41 patients, with 
hysteroscopy prior to IVF but with normal hyster-
oscopic findings; and the III control group of 151 pa-
tients with no hysteroscopy. 
Hysteroscopy was performed during oral contracep-
tive therapy, 3050 days before IVF. Saline solution 
was used as a distension medium and a 5mm Bettocchi 
office hysteroscope (Karl Storz GmbH and co, Tut-
tlingen, Germany) with a 5Fr working channel. The 
patients were in a lithotomy position all with short 
termed intravenous anesthesia applied. Vaginoscopic 
approach was used with no ecarter and no cervix trac-
tion.  Versapoint and Springle electrode (Johnson) were 
used in cases of polypectomy, septum resections and 
smaller myomas. In one case only, with a wider myoma, 
a bipolar resectoscope was used with a 9mm outer 
cover. Polyps, myomas and unclear lesions were hysto-
pathologically evaluated.  
IVF procedure was performed 12 months post oral 
contraceptive therapy. Long and short protocol with 
GnRH agonists was used. Serial ultrasound checkups 
during controlled ovary hyperstimulation (COH) were 
done with a “Shimatzu” ultrasound device, starting with 
the 6
th
 day of stimulation. On finding 2 or more follicles 
larger than 18mm, patients got 10000 IU Pregnyl injec-
tion, and 3436 hours afterwards, a transvaginal oocytes 
pick-up was performed (OPU). Embryo transfer (ET) 
was done on the 2
nd
, 3
rd
 or 5
th
 day after the aspiration, 
monitored by an ultrasound, putting back 3 embryos at 
the most. “Cook’s” catheter was used for the ET. The 
same therapy was applied for all patients, after ET: 
Utrogestan 200mg tablets, 3 times a day; Cardiopirin 
100mg tablets, once a day; Dexason 0.5mg tabl., once a 
day. ßHCG from blood was determined for biochemical 
verification of pregnancy, 15 days post OPU. Clinical 
pregnancies were verified by transvaginal ultrasound 
check up, by visualization of the embryo’s cardiac ac-
tivity, 45 weeks after ET. 
This prospective clinical trial was approved by the 
Ethics Committee. The treatment of the patients in-
cluded hysteroscopy and a long and short GnRH agonist 
protocol. Written informed consent was provided from 
all the patients participating in the study.   
The data were processed by standard descriptive statis-
tical methods (average value, percentage representation). 
The statistical processing was done among defined groups. 
Continual variables relative to data distribution were com-
pared using Student’s t-test, Pearson’s χ² test or ANOVA 
test.  
Results 
The patients from the examined groups were not signifi-
cantly different in any of the generally examined pa-
rameters (Table 1). 
There are also no statistically significant differences 
among the groups considering: the number of oocytes, 
conceived embryos, transferred embryos, and the day of 
embryo transfer as well (Table 2). The long protocol 
with agonists was most frequently used in the control 
group when compared to the I group, at a statistical 
level of significance p<0.05. Based on the general pa-
rameters and the features of the IVF cycle, homogeneity 
of the groups is present, which makes further results 
valid for this research. 
Presence of pathological states in the group of pa-
tients with hysteroscopy was 44.59% (Table 3), with 
endometrial polyp as the most common pathological 
state (63.64%), shown in Graph 1. There is no statisti-
cally significant difference in the incidence of uterus 
cavum pathological states between the first and the next 
IVF (Table 4). 
Although the implantation rate is higher in hyster-
oscopic groups 1 and 2, compared to the control group 
(20.62% vs 23.28% vs 17.31%), and the pregnancy rate as 
well (45.45% vs 46.34% vs 34.44%), there are no signifi-
cant differences between the groups. There is no statisti-
cally important difference neither in the multiple preg-
nancy rate nor in the rate of biochemical pregnancy, com-
paring all the three groups (Table 5). 
Table 1 General parameters of patients in examined groups 
 
I group 
(n = 33) 
II group 
(n = 41) 
III – Control group 
(n = 151) 
Age (years) 34.00  2.97 (33.00) 34.00  3.49 (35.00) 33.61  3.65 (34.00) 
Patients per age group    
≤30 years  
3135 years  
3640 years 
3 (09.09%) 
18 (54.55%) 
12 (36.36%) 
7 (17.07%) 
19 (46.34%) 
15 (36.59%) 
34 (22.52%) 
61 (40.40%) 
56 (37.09%) 
Duration of infertility (years) 7.12  3.53   (6.00) 5.93  2.86   (6.00) 6.38  3.58   (6.00) 
FSH (mIU/mL) 6.91  3.10   (6.45) 6.88  2.90   (6.10) 5.93  2.59   (5.50) 
AMH (ng/ml) 3.31  3.08   (2.32) 2.92  2.88   (1.84) 3.02  2.47   (2.18) 
BMI (kg/m²) 23.85  2.60 (24.00) 23.59  2.96 (23.00) 23.50  2.95 (23.00) 
Data are given as absolute numbers (percentages), means  SD (medians) 
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Table 3 Presence of pathological findings in the study 
group 
Group Patient nb   Total % 
I + II group 74 100,00% 
I group 33 44.59% 
II group 41 55.41% 
Table 2 The IVF cycle features of patients in the examined groups. 
 I group II group III – Control group 
Gonadotropin (IU) 2081.24  804.63 (1850.00) 2078.66  710.05 (1975.00) 2019.97  674.64 (1950.00) 
No. of oocytes  9.55  5.08 (9.00) 10.73  7.37 (10.00) 9.98  6.58 (8.00) 
No. of embryos 5.73  3.46 (5.00) 5.59  3.54 (5.00) 4.89  3.22 (4.00) 
No. of transferred 
embryos 
2.94  0.83 (3.00) 2.58  0.41 (3.00) 2.68  0.20 (3.00) 
Protocol 
Long agonists  
Short agonists  
 
16 (48.49%) 
17 (51.51%) 
 
27 (65.85%) 
14 (34.15%) 
 
98
 a*
 (64.90%) 
53 (35.10%) 
Endometrial 
thickness (mm) 
10.23  1.81 (10.00) 9.98  1.57 (10.00) 10.02  1.72 (10.00) 
First / second IVF 20 (60.60%) / 13 (39.40%) 26 (63.41%) / 15 (36.59%) 108 (71.52%) / 43 (28.48%) 
ET day  
2
nd
 day (%) 
3
rd
 day (%) 
5
th
 day (%) 
3.83  1.03 (3.00) 
0 (0.00%) 
21 (63.64%) 
12 (36.36%) 
3.34  0.94 (3.00) 
4 (9.76%) 
28 (68.29%) 
9 (21.95%) 
3.65  0.98 (3.00) 
4 (2.65%) 
96 (63.58%) 
51 (33.77%) 
Data are given as absolute numbers (percentages), means  SD (medians) 
*  p<0.05, a  vs I group 
 
Graph 1. Percentage of presence of pathological findings in I group  
Table 4 Presence of pathological findings in I group 
related to the first and second IVF 
 
First IVF 
n=20 
Second IVF 
n=13 
Polypus 14 70.00% 7 53.85% 
Septum 5 25.00% 3 23.08% 
Chronic endometritis 1 5.00% 2 15.38% 
Myoma 1 5.00% 1 7.69% 
Mycropolyposis 0 0.00% 1 7.69% 
Table 5 IVF features of patients in the examined groups 
 I group II group III – Control group 
Implantation rate 20.62% 20 / 97 23.28% 27 / 116 17.31% 72 / 416 
Clinical pregnancy rate 45.45% 15 / 33 46.34% 19 /   41 34.44% 52 / 151 
Biochemical pregnancy rate 12.12% 4 / 33 12.20% 5 /   41 6.62% 10 / 151 
Multiple pregnancy rate 33.33% 5 / 15 36.84% 7 /   19 36.54% 19 /   52 
Data are given as absolute numbers (percentages) 
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Significantly higher pregnancy rate is present in I 
group after the first IVF cycle in comparison to the se-
cond IVF in the same group (60.00% vs 23.08%, 
p<0.05), and also between the first IVF cycle in I group 
compared to the second IVF in the control group 
(60.00%vs 27.91%, p<0.05) (Table 6). 
After hysteroscopic polypectomy, highest pregnancy 
rate was achieved in comparison to uterus cavum 
pathological states. However, a number of patients did 
not allow statistical verification (Table 7). 
Table 7 Pregnancy rate in relation to the pathological 
findings 
Hysteroscopic 
findings 
Patient nb/ Pregnancy nb % pregnancy  
Polypus 21 / 12 57.14% 
Septum 8 / 3 37.50% 
Myoma 2 / 0 0.00% 
Chronic 
endometritis 
3 / 1 
33.33% 
Mycropolyposis 1 / 0 0.00% 
Discussion 
Regardless of the quality of embryos, an appropriate 
endometrial thickness and a successful embryo transfer 
(ET), unsuccessful implantation remains a major cause of 
IVF method failure. Repetitive implantation failure (RIF) 
is defined as no conception after two or more alternate 
transfers of one or more adequate quality embryos. All 
uterus cavum pathological states have a negative impact 
on the implantation rate. Their diagnostics is one of the 
primary goals before entering the IVF cycle.  
Our research showed cavum pathology incidence of 
44.59% with the largest presence of endometrial polyps, 
in nearly 2/3 of the cases (63.64%). Fatemi [1] found 
the frequency of only 11% of uterus pathology, whereas 
Cenksoy [8] discovered pathological states in 44.9% of 
the patients. In those two studies, endometrial polyp was 
the most common, but still in a smaller percentage than 
in our research, 6- 19.7%. In his journal article, Koda-
man [9] discovers a post IVF conceiving benefit from 
hysteroscopic polypectomy, explaining that an endome-
trial injury during the intervention is a reason of in-
creased endometrial receptivity. Polyp treatment options 
are: cancellation of the cycle and polypectomy, poly-
pectomy and freezing of embryos with ET after a few 
months’ period, or ignoring the polyps and continuation 
of the cycle [10]. 
Even though the implantation and pregnancy rates 
after cavum pathology treatment are higher than in the 
control group, our research did not lead to any statisti-
cally significant differences.  Comparing the IVF out-
comes in the first group of patients with clear hyster-
oscopic findings, similar percentage can be seen. That is 
in accordance with numerous studies proving the benefit 
of performing hysteroscopy prior to IVF with patients 
having pathological substratum and specifying better 
IVF results after polypectomy, myomectomy or septum 
uterus resection [7,11,12]. 
The influence of hysteroscopy itself on the IVF out-
come has been considered for quite a long time, advo-
cating hysteroscopy prior to every IVF cycle. In favor of 
that, many projects discuss the impact of local endome-
trial injury during hysteroscopy which brings about en-
dometrial inflammation, thus increasing the endometrial 
receptivity [13].  
In their meta-analyses, Pundir and El-Toukhy found 
the proof of the hysteroscopy benefit prior to the first 
IVF cycle, proving a higher pregnancy rate with women 
who underwent hysteroscopy procedure [4]. One more 
research with 480 patients also showed higher preg-
nancy rates when hysteroscopy was performed before 
the first IVF [14]. Our study did not provide information 
about hysteroscopy itself influencing statistically better 
IVF outcome results. Pregnancy rate in II group is sta-
tistically not different from the pregnancy rates neither 
in I group nor in the control group (46.34% vs 45.45% 
vs 34.44%). 
Latest randomized multicentral studies showed that 
if the ultrasonography result is normal, there is no in-
creased pregnancy rate after hysteroscopy. They also 
showed that there is no significant difference even if 
hysteroscopy is being performed after repetitive failed 
IVF cycles, unless there are pathological changes in the 
uterus cavum [5,6]. 
Conclusion 
Hysteroscopy is a safe method enabling reliable diag-
nostics of all uterus cavum pathological states which 
have a negative impact on the IVF outcome. It allows a 
simultaneous surgical treatment of the pathological 
changes within the same procedure and it gives a similar 
IVF outcome as with patients who have clear cavum 
Table 6 Pregnancy rate in the examined groups, with first and second IVF cycle compared. 
 First VTO Second VTO 
Group  Patient nb/ Pregnancy nb % pregnancy Patient nb/ Pregnancy nb % pregnancy 
I group  20 12
*cd
 60.00% 13 3 23.08% 
II group  26              13  50.00% 15 6 40.00% 
III–Control group 108             40  37.04% 43 12 27.91% 
Total 158             65  41.14% 74 27 36.49% 
Data are given as absolute numbers (percentages) 
*
  p<0.05, c  vs control, d  vs second IVF 
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findings. In case of normal ultrasonography findings, 
there are no statistically better results in the IVF proce-
dure after hysteroscopy. Therefore, routine hyster-
oscopy prior to the first IVF is not recommended, as 
well as after repetitive implantation failures. 
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